Related Experiment Videos

Population-based studies of antithyroid drugs and sudden cardiac death

Charlotte van Noord1, Miriam C J M Sturkenboom, Sabine M J M Straus

  • 1Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.

British Journal of Clinical Pharmacology
|September 11, 2009
PubMed

Insights

Antithyroid drug use is linked to a threefold increased risk of sudden cardiac death (SCD). This association may stem from the drugs themselves or indicate poorly controlled hyperthyroidism, a known cardiac risk factor.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Thyroid hormones influence cardiac function, and free T4 levels are linked to QTc-interval prolongation, a risk factor for sudden cardiac death (SCD).
  • While hyperthyroidism has been anecdotally linked to SCD, population-based evidence is lacking.
  • Antithyroid drugs are used to manage hyperthyroidism, but their direct association with SCD risk is unclear.

Purpose of the Study:

  • To investigate the association between antithyroid drug use and the risk of sudden cardiac death (SCD).
  • To determine if antithyroid drug use is an independent risk factor for SCD or an indicator of poorly controlled hyperthyroidism.

Main Methods:

  • A two-step population-based study was conducted in the Netherlands, utilizing the Rotterdam Study and the Integrated Primary Care Information (IPCI) database.
  • Cohort analysis (Rotterdam Study) and case-control analysis (IPCI) were employed to assess SCD occurrence.
  • Drug use was determined from pharmacy records and general practice data, with statistical models adjusted for relevant covariates.

Main Results:

  • In the Rotterdam Study, current antithyroid drug use was associated with a 3.9-fold increased risk of SCD.
  • The IPCI database analysis revealed a 2.9-fold increased risk of SCD associated with current antithyroid drug use.
  • Both studies demonstrated a statistically significant association between antithyroid drug use and SCD.

Conclusions:

  • Antithyroid drug use is associated with a significantly increased risk of sudden cardiac death.
  • This increased risk may be directly attributable to the antithyroid drugs or, more likely, reflect underlying poorly controlled hyperthyroidism.
  • Low thyroid-stimulating hormone levels in patients who died from SCD suggest persistent hyperthyroidism as a potential driver of risk.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...